NCT06627231View on ClinicalTrials.gov

Mass Balance Clinical Trial With TEV-56286

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

October 8, 2024

Primary Completion Date

November 29, 2024

Study Completion Date

November 29, 2024

Conditions
Healthy Participants
Interventions
DRUG

TEV-56286

Oral capsule

DRUG

[14C]-TEV-56286

Oral capsule

Trial Locations (1)

9728 NZ

Teva Investigational Site 38189, Groningen

All Listed Sponsors
lead

Teva Branded Pharmaceutical Products R&D, Inc.

INDUSTRY

NCT06627231 - Mass Balance Clinical Trial With TEV-56286 | Biotech Hunter | Biotech Hunter